16110030Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CDJournal of clinical oncology : official journal of the American Society of Clinical OncologyAntineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Leukemia, MyeloidAcute Disease; Aged; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival AnalysisPrognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.J Clin Oncol2005-08-20T00:00:002005Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000208Disorders3298240.843097Acute DiseaseD001388Chemicals & Drugs690.998847AziridinesD000368Living Beings1341183530.294764AgedD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD003520Chemicals & Drugs1242990.920618CyclophosphamideD003630Chemicals & Drugs23780.969474DaunorubicinD005047Chemicals & Drugs621960.939617EtoposideD003561Chemicals & Drugs512180.93221CytarabineD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD008942Chemicals & Drugs38680.968189MitoxantroneAuthorship 2773514D005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD016227Chemicals & Drugs21270.987117BenzoquinonesAuthorship 2773611D007951Disorders552490.883124Leukemia, MyeloidD008297Physiology1931408600.201617MaleD016016Concepts & Ideas3048570.817586Proportional Hazards Models0.06885140.06885142authors10.2522has subject areaMedicine-Hematology and OncologyD011379Procedures74536690.561447PrognosisD016019Concepts & Ideas43415360.742907Survival AnalysisD018709Concepts & Ideas2173070.933873Statistics, NonparametricD002869Disorders1113860.870742Chromosome AberrationsD011446Concepts & IdeasProcedures85541940.532013Prospective StudiesD012074Procedures1657220.853019Remission InductionPathologyUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorJamesVardimanJames W. Vardiman41.78927490000000-87.601250000000001630Vardiman, JamesEmeritus/Emeritatrue1ProfessorProfessortrue1Emeritus/EmeritaEmeritus/Emerita